Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03558048 · ClinicalTrials.gov registry record
The Effect of IBD Flares on Serum PSA
A clinical trial of Prostate Cancer and Inflammatory Bowel Diseases, sponsored by Northwestern University.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT03558048: Recruiting study of Prostate Cancer and Inflammatory Bowel Diseases, sponsored by Northwestern University.
NCT03558048 is a study of Prostate Cancer and Inflammatory Bowel Diseases that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 400 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (34% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03558048, a study of Prostate Cancer and Inflammatory Bowel Diseases, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will measure Prostate Specific Antigen (PSA) values in men with Inflammatory Bowel Disease (IBD) before, during, and following a flare. In addition, the effect of any PSA increase will be analyzed and correlated to the location of disease (rectal vs. other). Study findings may help men with IBD by identifying pitfalls in prostate cancer screening for this population and help to stratify and understand the effect IBD has on the prostatic milieu. By optimizing how men with IBD are screened for prostate cancer, future unnecessary healthcare encounters and expenditures may be reduced for this patient group.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Blood draw
Study Locations (1)
Illinois
- Northwestern Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2025-10-01 |
What NCT03558048 shows while recruiting
NCT03558048 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (34% lower).
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT03558048 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT03558048 about?
NCT03558048 is a clinical study titled "The Effect of IBD Flares on Serum PSA". This study will measure Prostate Specific Antigen (PSA) values in men with Inflammatory Bowel Disease (IBD) before, during, and following a flare. In addition, the effect of any PSA increase will be analyzed and correlated to the location of disease (rectal vs. other). Study findings may help men wi...
What is the current status of trial NCT03558048?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2019-08-01. Estimated completion is 2025-10-01.
What conditions does trial NCT03558048 study?
This clinical trial studies the following conditions: Prostate Cancer, Inflammatory Bowel Diseases.
What interventions are being tested in trial NCT03558048?
The interventions under investigation include: Blood draw (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03558048?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03558048 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03558048's enrollment target sits among peer trials
400 128th of 735 higher than 605 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy
RECRUITING
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI